HomeNewsBusinessEconomyCoronavirus pandemic: To prevent NPAs, government needs to infuse specific fund related capital

Coronavirus pandemic: To prevent NPAs, government needs to infuse specific fund related capital

For credit flow to remain smooth, public-sector banks need to be recapitalised adequately or issue a promise of capital, so that the banks are able to provide for the impending surge in NPAs

April 16, 2020 / 13:58 IST
Story continues below Advertisement

One of biggest fallouts of the COVID-19 outbreak in India would be a surge in banks' non-performing assets (NPAs).

Banks and non-banking finance companies are staring at the possibility of a huge surge in NPAs, not just from the corporate sector loans but also retail loans. A complete pause in economic activities and impending uncertainty in employment would see companies and households struggle to deal with the fallout.

Story continues below Advertisement

In order to revive growth once the tide turns, lenders would need to lend aggressively. "So when initially, the problem began, instead of running after the money or running after the borrower, our systems started running after bankers. And that created a huge behavioural issue in the country and paralyzed decision-making. And this problem still persists. Decision making is still a bit of a challenge," said Ashvin Parekh, the managing partner at Ashvin Parekh Advisory Services.

The COVID-19 outbreak has led to the stock market crashing and which in turn would make it difficult for private sector banks to raise capital.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show